VESTECK, Inc.

VESTECK, Inc. is a medical technology company focused on developing innovative solutions for endograft fixation, primarily through its advanced Suture-Tight™ platform that enhances the effectiveness of endovascular aortic repair procedures. VESTECK, Inc. specializes in medical solutions for endograft fixation.

The company is headquartered in the US. Joseph Rafferty serves as the CEO. In August 2021, VESTECK, Inc. raised USD 4.

3 mn in Series A funding led by New World Angels, with participation from DeepWork Capital, Ocean Azul Partners, Ben Franklin Technology Partners, Robin Hood Ventures, and the Delaware Crossing Investor Group. The total amount raised by the company amounts to USD 4. 3 mn. VESTECK, Inc.

specializes in innovative medical solutions focused on endograft fixation through its flagship product, Suture-Tight™. This advanced endosuturing platform is designed to enhance the effectiveness of endovascular aortic repair (EVAR) and thoracic endovascular aortic repair (TEVAR) procedures. By providing a method for securing endografts within the vascular system, Suture-Tight™ addresses critical challenges related to device stability and patient outcomes post-surgery. The company primarily serves healthcare providers, including hospitals and surgical centers, that perform vascular interventions.

VESTECK aims to penetrate key markets across North America and Europe, where the demand for minimally invasive surgical solutions is growing. VESTECK, Inc. operates with a revenue model centered around B2B transactions, primarily targeting medical institutions and surgical facilities. Sales of Suture-Tight™ are structured through direct contracts with hospitals, where pricing is determined based on negotiated agreements tailored to the needs of each client.

Transactions typically involve bulk purchasing arrangements or long-term supply contracts, allowing healthcare providers to efficiently incorporate the endosuturing platform into their surgical offerings. The company’s revenue streams will be bolstered by partnerships with medical distributors, facilitating broader market access and integration into existing procurement frameworks within the healthcare sector. In August 2021, VESTECK, Inc. raised USD 4.

3 mn in Series A funding to support the manufacturing of products, pre-clinical testing, and completion of in-human procedures before clinical studies for FDA clearance. The company plans to expand its product line with new innovations in the endograft fixation space and targets expansion into new markets across North America and Europe by 2023. The recent funding will significantly enhance their research and development efforts, allowing VESTECK to accelerate product launches and improve their market presence.